ASLAN Pharmaceuticals Limited
Stock Forecast, Prediction & Price Target
ASLAN Pharmaceuticals Limited Financial Estimates
ASLAN Pharmaceuticals Limited Revenue Estimates
ASLAN Pharmaceuticals Limited EBITDA Estimates
ASLAN Pharmaceuticals Limited Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | |
Revenue
% change YoY
| $0 N/A | $0 0% | $12M 0% | Avg: $6.75M Low: $6.75M High: $6.75M avg. -43.75% | Avg: $5.06M Low: $5.06M High: $5.06M avg. -25% | Avg: $3.79M Low: $3.79M High: $3.79M avg. -25% | |
Net Income
% change YoY
| $-34.70M N/A | $-51.38M -48.03% | $-44.21M 13.94% | Avg: $-54.74M Low: $-38.65M High: $-38.65M avg. -23.80% | Avg: $-21.38M Low: $-21.38M High: $-21.38M avg. 60.93% | Avg: $-24.51M Low: $-24.51M High: $-24.51M avg. -14.61% | |
EBITDA
% change YoY
| $-32.03M N/A | $-47.60M -48.59% | $-43.38M 8.86% | Avg: $1.34M Low: $1.34M High: $1.34M avg. 103.11% | Avg: $1.01M Low: $1.01M High: $1.01M avg. -25.00% | Avg: $759.37K Low: $759.37K High: $759.37K avg. -25.00% | |
EPS
% change YoY
| -$2.66 N/A | -$3.68 -38.34% | -$2.69 26.90% | Avg: -$2.35 Low: -$2.35 High: -$2.35 avg. 12.63% | Avg: -$1.3 Low: -$1.3 High: -$1.3 avg. 44.68% | Avg: -$1.49 Low: -$1.49 High: -$1.49 avg. -14.61% | |
Operating Expenses
% change YoY
| $33.84M N/A | $47.88M 41.46% | $55.38M 15.67% | Avg: $9.33M Low: $9.33M High: $9.33M avg. -83.15% | Avg: $6.99M Low: $6.99M High: $6.99M avg. -25.00% | Avg: $5.24M Low: $5.24M High: $5.24M avg. -25.00% | |
FAQ
What is ASLAN Pharmaceuticals Limited stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 7.50% in 2025-2027.
We have gathered data from 1 analysts. Their low estimate is -38.65M, average is -54.74M and high is -38.65M.
What is ASLAN Pharmaceuticals Limited stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of -31.25% in 2025-2027.
We have gathered data from 1 analysts. Their low revenue estimate is $6.75M, average is $6.75M and high is $6.75M.
What is ASLAN Pharmaceuticals Limited stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 14.23% in 2025-2027.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$2.35, average is -$2.35 and high is $-2.35.
What is the best performing analyst?
In the last twelve months analysts have been covering ASLAN Pharmaceuticals Limited stock. The most successful analyst is Edward Tenthoff whose win rate is 100%. He has correctly predicted 1/1 price targets.